On-‘DEMAND’ data: Sarepta, Prosensa return DMD optimism
By Jennifer Boggs
Friday, January 17, 2014
SAN FRANCISCO – After clinical and regulatory setbacks in the latter part of 2013, the news might be getting better for patients with Duchenne’s muscular dystrophy (DMD), as two of the most advanced programs reported news at the J.P. Morgan Healthcare Conference.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.